Global Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025
- Published Date: Apr 2018
- Pages: 90
- Format: PDF
- Report ID: PM1238
- Base Year: 2017
- Historical Data: 2015-2016
Suggested Report
- Non-Invasive Prenatal Testing (NIPT) Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Vascular Access Device Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Liver Disease Diagnostics Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
- Astaxanthin Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok